CIIS Psychedelic-Assisted Therapies Certificate: 2026-2027 Cohort Now Open

For clinicians considering psychedelic-assisted work after the FDA's Lykos rejection and the slow Oregon/Colorado rollouts, training infrastructure now matters more than regulatory speed. CIIS's program — running since 2016, the first university-affiliated psychedelic certificate — remains the de-facto reference standard against which Compass, Fluence, and newer entrants are measured. The 2026-2027 cohort is the tenth iteration, and several details are worth attention before applying.

What the program actually teaches

Five modules run in parallel across the year. Module 1 covers pharmacology, neuroscience, regulatory landscape, and current MDMA/psilocybin/ketamine clinical research. Module 2 is the cultural-spiritual layer: indigenous traditions, mystical experience, group ceremonial work. Module 3 is the clinical core — facilitator competencies, cultural humility, ethics, safety, structural competency. Module 4 covers preparation, session, and integration practices in both group and individual formats. Module 5 is experiential: Holotropic Breathwork, guided imagery, role-play of psychedelic sessions, drumming inductions. The Hybrid SF Cohort embeds Holotropic Breathwork in tuition; Online cohort trainees can add it for $600.

Eligibility extends beyond licensed clinicians to graduates with M.A.+ degrees in social sciences, allied health, humanities, sciences, law, or "compatible" fields. International applicants are explicitly encouraged. Twelve U.S. states (AL, AR, DE, DC, IA, KS, MN, MS, NJ, NC, ND, WI) cannot enroll due to state authorization rules — relevant if you are advising U.S. colleagues. The Oregon subcohort is the only path here that leads to actual legal practice: 40 hours of in-person didactics in Portland plus consultation work at OHA-approved service centers, then the CIIS Oregon exam, then the OHA license. Out-of-state residents may now apply for the Oregon license under updated statute 333-333-4050, but psilocybin work itself must occur at Oregon service centers.

For your practice

Treat the certificate as a foundation, not a credential to advertise. None of MDMA, psilocybin, or ayahuasca is FDA-approved for therapeutic use; ketamine remains the only legal pathway in most U.S. states, and KAP requires medical co-prescribing infrastructure that the certificate does not by itself provide. The realistic post-certificate trajectories: research therapist roles in clinical trials (where regulations evolve), legal ketamine-assisted psychotherapy practice if you build the medical partnership, and psychedelic integration work — supporting clients who pursue these experiences through other channels and need clinical containment afterward. The integration track is the largest immediate market and the most defensible scope of practice. The Oregon subcohort is the only certified-facilitator pipeline; it adds time, cost, and a state-specific licensing exam, and you can practice only inside Oregon.

What sets the program apart from shorter certificates is the experiential component and the mentorship hours. Eight weekends of didactics will not make you competent at holding a 6-hour non-ordinary state — Module 5 and the 30 hours of mentor consultation are what move trainees toward that. If you already hold a clinical license in a state with active KAP practice or work in a research center, the ROI is clearest. If you are non-licensed and joining for personal-philosophical reasons, that is allowed but should be honest with yourself about the post-certificate scope.